Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Catapano

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Molecular Therapy. Nucleic Acids|July 6, 2016
Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide TherapyFrancesco Catapano, Irina Zaharieva, Mariacristina Scoto, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 15, 2020
Abnormal bodily experiences detected by Abnormal Bodily Phenomena questionnaire are more frequent and severe in schizophrenia than in bipolar disorder with psychotic featuresGiovanni Stanghellini, Davide Palumbo, Massimo Ballerini, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|December 18, 2009
Obsessive-compulsive disorder with poor insight: a three-year prospective studyFrancesco Catapano, Francesco Perris, Michele Fabrazzo, et al.
Frontiers in Psychiatry|July 3, 2019
Comorbidity of Obsessive-Compulsive Disorder and Schizotypal Personality Disorder: Clinical Response and Treatment Resistance to Pharmacotherapy in a 3-Year Follow-Up Naturalistic StudyFrancesco Perris, Michele Fabrazzo, Valeria De Santis, et al.
Psychiatry Research|June 27, 2017
Clozapine versus other antipsychotics during the first 18 weeks of treatment: A retrospective study on risk factor increase of blood dyscrasiasMichele Fabrazzo, Vincenzo Prisco, Gaia Sampogna, et al.
Clinical Schizophrenia & Related Psychoses|December 21, 2016
Brain Natriuretic Peptide as a Biomarker of Asymptomatic Clozapine-Related Heart Dysfunction: A Criterion for a More Cautious AdministrationVincenzo Prisco, Petrosino Monica, Germano Fiore, et al.
Frontiers in Psychiatry|April 25, 2022
Delirium and Psychiatric Sequelae Associated to SARS-CoV-2 in Asymptomatic Patients With Psychiatric History and Mild Cognitive Impairment as Risk Factors: Three Case ReportsMichele Fabrazzo, Antonio Russo, Mario Luciano, et al.
Cells|March 6, 2020
Exosomes: From Potential Culprits to New Therapeutic Promise in the Setting of Cardiac FibrosisRoman Tikhomirov, Benedict Reilly-O' Donnell, Francesco Catapano, et al.
Rivista Di Psichiatria|July 1, 2016
[Drug safety warnings in psychiatry: adverse drug reactions' signaling from 2002 to 2014]Vincenzo Prisco, Teresa Iannaccone, Adriano Tusciano, et al.
Clinics and Practice|March 26, 2025
Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case ReportSalvatore Cipolla, Flora Delli Carpini, Pierluigi Catapano, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Molecular Therapy. Nucleic Acids|July 6, 2016
Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide TherapyFrancesco Catapano, Irina Zaharieva, Mariacristina Scoto, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 15, 2020
Abnormal bodily experiences detected by Abnormal Bodily Phenomena questionnaire are more frequent and severe in schizophrenia than in bipolar disorder with psychotic featuresGiovanni Stanghellini, Davide Palumbo, Massimo Ballerini, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|December 18, 2009
Obsessive-compulsive disorder with poor insight: a three-year prospective studyFrancesco Catapano, Francesco Perris, Michele Fabrazzo, et al.
Frontiers in Psychiatry|July 3, 2019
Comorbidity of Obsessive-Compulsive Disorder and Schizotypal Personality Disorder: Clinical Response and Treatment Resistance to Pharmacotherapy in a 3-Year Follow-Up Naturalistic StudyFrancesco Perris, Michele Fabrazzo, Valeria De Santis, et al.
Psychiatry Research|June 27, 2017
Clozapine versus other antipsychotics during the first 18 weeks of treatment: A retrospective study on risk factor increase of blood dyscrasiasMichele Fabrazzo, Vincenzo Prisco, Gaia Sampogna, et al.
Clinical Schizophrenia & Related Psychoses|December 21, 2016
Brain Natriuretic Peptide as a Biomarker of Asymptomatic Clozapine-Related Heart Dysfunction: A Criterion for a More Cautious AdministrationVincenzo Prisco, Petrosino Monica, Germano Fiore, et al.
Frontiers in Psychiatry|April 25, 2022
Delirium and Psychiatric Sequelae Associated to SARS-CoV-2 in Asymptomatic Patients With Psychiatric History and Mild Cognitive Impairment as Risk Factors: Three Case ReportsMichele Fabrazzo, Antonio Russo, Mario Luciano, et al.
Cells|March 6, 2020
Exosomes: From Potential Culprits to New Therapeutic Promise in the Setting of Cardiac FibrosisRoman Tikhomirov, Benedict Reilly-O' Donnell, Francesco Catapano, et al.
Rivista Di Psichiatria|July 1, 2016
[Drug safety warnings in psychiatry: adverse drug reactions' signaling from 2002 to 2014]Vincenzo Prisco, Teresa Iannaccone, Adriano Tusciano, et al.
Clinics and Practice|March 26, 2025
Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case ReportSalvatore Cipolla, Flora Delli Carpini, Pierluigi Catapano, et al.
Pageof 6